- Home
- ILLR vs RCEL Comparison
ILLR vs RCEL Comparison
Compare ILLR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- RCEL
- Stock Information
- Founded
- ILLR 2015
- RCEL N/A
- Country
- ILLR United States
- RCEL United States
- Employees
- ILLR N/A
- RCEL N/A
- Industry
- ILLR Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- ILLR Finance
- RCEL Health Care
- Exchange
- ILLR Nasdaq
- RCEL Nasdaq
- Market Cap
- ILLR 304.1M
- RCEL 308.6M
- IPO Year
- ILLR N/A
- RCEL N/A
- Fundamental
- Price
- ILLR $1.18
- RCEL $9.75
- Analyst Decision
- ILLR
- RCEL Buy
- Analyst Count
- ILLR 0
- RCEL 5
- Target Price
- ILLR N/A
- RCEL $17.25
- AVG Volume (30 Days)
- ILLR 644.6K
- RCEL 191.4K
- Earning Date
- ILLR 03-04-2025
- RCEL 02-13-2025
- Dividend Yield
- ILLR N/A
- RCEL N/A
- EPS Growth
- ILLR N/A
- RCEL N/A
- EPS
- ILLR N/A
- RCEL N/A
- Revenue
- ILLR $45,244,000.00
- RCEL $64,251,000.00
- Revenue This Year
- ILLR N/A
- RCEL $62.11
- Revenue Next Year
- ILLR N/A
- RCEL $31.19
- P/E Ratio
- ILLR N/A
- RCEL N/A
- Revenue Growth
- ILLR N/A
- RCEL 28.14
- 52 Week Low
- ILLR $0.66
- RCEL $7.51
- 52 Week High
- ILLR $8.86
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- RCEL 50.10
- Support Level
- ILLR N/A
- RCEL $8.37
- Resistance Level
- ILLR N/A
- RCEL $11.25
- Average True Range (ATR)
- ILLR 0.00
- RCEL 0.55
- MACD
- ILLR 0.00
- RCEL 0.22
- Stochastic Oscillator
- ILLR 0.00
- RCEL 47.92
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.